All In Biotech

Drug Trial Radar · NCT06694805

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

A Phase 3b, Open Label, Randomized, standard-of Care Control Arm, Multicenter, Superiority Study Evaluating the Efficacy, Safety, and Tolerability of Injectable CAB LA + RPV LA in Viremic Participants Living With HIV-1 (CROWN)

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 326 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

326

Actual

Start

Dec 2, 2024

Primary completion

Aug 19, 2026

Study completion Jun 9, 2028

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
First posted
Nov 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess how effective, safe, and long-lasting a long-acting antiretroviral therapy (ART) using CAB LA + RPV LA is for people with HIV who still have detectable virus levels despite being on oral ART. The study will also consider feedback from patients on their experience with this treatment.

Conditions

  • HIV Infections

Interventions

  • CAB LA + RPV LADrug

    Intramuscular injection administered monthly for first 2 initiation doses then every 2 months.

  • Oral ARTDrug

    Oral medication provided to participants by the site/their regular healthcare professional (HCP) as part of their standard of care (SOC) treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with virologic suppression after the CAB LA + RPV LA treatment compared to oral ARTTime frame: At Month 6

Locations

85 sites in 8 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Aurora, Colorado

  • GSK Investigational Site

    Denver, Colorado

  • GSK Investigational Site

    New Haven, Connecticut

  • GSK Investigational Site

    Newark, Delaware

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Jacksonville, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Sarasota, Florida

  • GSK Investigational Site

    West Palm Beach, Florida

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    Decatur, Georgia

  • GSK Investigational Site

    Macon, Georgia

  • GSK Investigational Site

    Chicago, Illinois

  • GSK Investigational Site

    Chicago, Illinois

  • GSK Investigational Site

    Chicago, Illinois

  • GSK Investigational Site

    Baltimore, Maryland

  • GSK Investigational Site

    Baltimore, Maryland

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Berkley, Michigan

  • GSK Investigational Site

    Kansas City, Missouri

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Newark, New Jersey

  • GSK Investigational Site

    Hawthorne, New York

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    The Bronx, New York

  • GSK Investigational Site

    The Bronx, New York

  • GSK Investigational Site

    Greensboro, North Carolina

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    Columbus, Ohio

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Seattle, Washington

  • GSK Investigational Site

    Milwaukee, Wisconsin

  • GSK Investigational Site

    Buenos Aires, Argentina

Showing 40 of 85 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.